MADISON, N.J. — Bausch + Lomb, the global eye health company, has acquired the rights to a novel platform technology for treating posterior segment diseases of the eye.
This promising new addition to Bausch + Lomb’s pipeline has already completed the “proof of principle” research phase, and if future trials and commercialization are successful, would reduce the need for ongoing pharmacological intervention.
“The addition of this novel technology to our development and research (D&R) pipeline reflects Bausch + Lomb’s strong commitment to patients with retinal diseases and the doctors who treat them,” said Dr. Cal Roberts, Chief Medical Officer, Bausch + Lomb. “Through partnership with leading retinal specialists, we hope to advance this innovative new science in order to preserve vision in patients suffering from posterior segment conditions.”
About Bausch + Lomb
Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.
# # #
News Media Contacts:
Bausch + Lomb Pharmaceuticals